StreetAlpha.app
Home › Stocks › RCUS

Arcus Biosciences, Inc. (RCUS)

Healthcare
$15.62
▼ −1.01%
LAST CLOSE · NOV 20

Arcus Biosciences develops investigational cancer medicines for patients and the doctors who treat them. It last closed at $15.62 on Nov 20, down 1.01% on the day. The next earnings report for RCUS is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, RCUS reported EPS of -$1.00 on revenue of $9.0M, with revenue down 65.4% from a year ago. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months RCUS insiders bought $0 of stock on the open market and sold $9.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is RCUS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RCUS.

Key Stats

Last 12 months
Results
Revenue
$100.0M
−58.3% vs a year ago
Net income
−$453.0M
−453.0% margin
EPS (diluted)
−$3.64
Free cash flow
−$466.0M
−466.0% margin
Valuation
Market cap
$2.2B
144.0M shares
P/E
–
No P/E while losing money
Price to sales
22.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$151.0M
At Sep 30
Debt
$102.0M
At Sep 30
Shareholder equity
$358.0M
Shares outstanding
144.0M
At Oct 29
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $383.0M$383.0MFY2021FY2022: $112.0M$112.0MFY2022FY2023: $117.0M$117.0MFY2023FY2024: $258.0M$258.0MFY2024FY2025: $247.0M$247.0MFY2025

From RCUS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
-$1.00
Quarter ended Sep 2026
Year ago EPS
-$1.27
Same quarter last year
Revenue
$9.0M
−65.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.03Dec '24Mar 2025: -$1.14Mar '25Jun 2025: $0.00Jun '25Sep 2025: -$1.27Sep '25Dec 2025: -$0.90Dec '25Mar 2026: -$1.02Mar '26Jun 2026: -$0.72Jun '26Sep 2026: -$1.00Sep '26Latest -$1.00
Revenue by quarter
Dec 2024: $26.0MDec '24Mar 2025: $28.0MMar '25Jun 2025: $160.0MJun '25Sep 2025: $26.0MSep '25Dec 2025: $33.0MDec '25Mar 2026: $17.0MMar '26Jun 2026: $41.0MJun '26Sep 2026: $9.0MSep '26Latest $9.0M
How RCUS moved after its last 8 reports
Average move the session after a report ±3.7%
Oct 21, 2026After the close+1.4%
Aug 5, 2026After the close+2.3%
May 5, 2026After the close−0.2%
Feb 25, 2026After the close−3.6%
Oct 28, 2025After the close+2.1%
Aug 6, 2025After the close−2.2%
May 6, 2025After the close−1.4%
Feb 18, 2025Time not announced−16.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RCUSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RCUS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RCUS

Technical Analysis

RCUS · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 14% below its 20 day and 37% below its 50 day average. It is 56% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $15.56, and the nearest resistance the Pivot at $15.95.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 7.2%/day
Key levels
$31.7352 week high+103.1%
$25.19100 day average+61.3%
$24.34200 day average+55.8%
$21.4750 day average+37.5%
$19.02Swing high (Oct 29)+21.8%
$17.7620 day average+13.7%
$16.33Pivot R1+4.5%
$15.95Pivot+2.1%
$15.62Last close
$15.5652 week low−0.4%
$15.23Pivot S1−2.5%
Indicators
RSI (14)28.58Oversold below 30Oversold
MACD-1.58Below its signal lineBearish
Stochastic1.7Near the bottom of its rangeOversold
ADX (14)33.3Trending down
Williams %R-98.5Oversold below −80, overbought above −20Oversold
CCI (20)-159.6Oversold below −100, overbought above 100Oversold
Rate of change−14.6%Change over 10 sessionsBearish
ATR (14)$1.12Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RCUS

What happened before

See how RCUS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RCUS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RCUS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RCUSHow many large options trades hit RCUS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RCUS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲132 buying vs 102 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +14
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding244230+6.1%
In funds' top 1056−16.7%
Held by funds86.8%85.1%+1.6 pts
New / increased47 / 8543 / 87+1.5%
Reduced / sold out72 / 3063 / 24+17.2%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RCUS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RCUS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$9.5M17 sales · 7 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $5.3M2026-01 sold $681K2026-05 sold $199K2026-06 sold $944K2026-07 sold $2.0M2026-08 sold $85KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 21Alexander AzoyChief Accounting OfficerSale plan2,827$30.00$85K
Jul 10Juan C. JaenPresidentSale plan68,569$29.63$2.0M
Jun 24Juan C. JaenPresidentSale plan31,431$27.92$878K
Jun 1Alexander AzoyChief Accounting OfficerSale plan2,562$25.77$66K
May 11II Robert C. GoeltzCFOSale plan7,763$25.63$199K
Jan 5Juan C. JaenPresidentSale plan31,823$21.41$681K
Every insider buy and sale for RCUS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RCUS insider trades →

From SEC Form 4 filings by RCUS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCUS is in one of them and how their past RCUS trades turned out.

RCUS in the AI portfolios
Loading…

RCUS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RCUS in an article yet. Here's the latest on the wider market.

RCUS in the news

About Arcus Biosciences

Arcus Biosciences is a biopharmaceutical company based in Hayward, California. It develops investigational medicines, mainly for cancer, and tests them in clinical trials carried out with contract research organizations and trial sites. Its products are still investigational, and it works with partners such as AstraZeneca, Gilead and Taiho on some of its programs. Its intended users are cancer patients and the doctors who treat them.

Headquarters
Hayward, CA
Founded
2015